Medicine Wellness Health 

HUMAN Diagnostics Announces the Launch of its Next Generation Clinical Chemistry Instruments

Primed for Precision. Built for Perfromance Wiesbaden, Germany – February 1, 2025 – HUMAN Diagnostics, a global player in in-vitro diagnostics, announces the launch of its advanced clinical chemistry instruments, scheduled to debut at Medlab Middle East in Dubai, from February 3-6, 2025. This milestone reflects HUMAN’s commitment to delivering innovative and reliable diagnostic solutions that meet the needs of modern laboratories worldwide. The launch is under the motto “ Primed for Precision. Built for Performance“ and will spotlight the next-generation HumaStar 300SR, HumaStar 200, and the HumaLyzer Primus NG,…

Mehr...
Medicine Wellness Health 

Proctocom 2024: RDG presents new standardized recommendations for LHP laser treatment of hemorrhoids

The recommendations of the LHP® Recommendation Development Group (RDG) published in November will contribute to the further standardization and refinement of laser hemorrhoidoplasty (LHP®) developed by biolitec® worldwide. Jena, 12.12.2024 – The LHP® Recommendation Development Group (RDG) published its recommendations for a standardized LHP® procedure on 23 November 2024.1 The group is made up of 49 surgeons with experience in the use of laser hemorrhoidoplasty – LHP® for short – developed by biolitec® for the minimally invasive treatment of hemorrhoids. The recommendations aim to improve the safety and efficacy of…

Mehr...

Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 Antibody

Düsseldorf, Tokyo and Novi, Michigan – December 11, 2024 – Asahi Kasei Pharma has taken another step in its transformation into a global specialty pharmaceuticals company through a new licensing agreement with Chiome Bioscience for its humanized anti-CX3CR1 antibody. The partnership exemplifies Asahi Kasei Pharma“s Open Innovation platform, which addresses unmet medical needs through strategic collaboration and cutting-edge science. The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites. By accelerating its development, Asahi Kasei Pharma aims to bring…

Mehr...
Medicine Wellness Health 

Asahi Kasei Microdevices Advances AgeTech with Better AI-Ready Data Through New Sensor Technologies

Devices will be demonstrated at CES 2025 Düsseldorf, Tokyo and Novi – November 13, 2024 – The desire to age in place is stronger than ever, with 95% of adults 55 and older considering it an important goal, according to U.S. News & World Report, even though health challenges often make it difficult. At CES 2025, Asahi Kasei Microdevices (AKM), part of Asahi Kasei Corporation, will unveil a suite of sensor technologies, including millimeter-wave (mmWave) radar and contactless monitoring. These technologies can make AgeTech more reliable and accessible while minimizing…

Mehr...
Medicine Wellness Health 

Asahi Kasei Medical launches Planova™ FG1 next-generation virus removal filter

Düsseldorf, Tokyo and New York – October 22, 2024 – Asahi Kasei Medical has launched the Planova™ FG1, a next-generation virus removal filter featuring higher flux for the manufacture of biotherapeutics, in October 2024. The bioprocess business of Asahi Kasei Medical comprises Planova™ virus removal filters and equipment used in the manufacturing process of biotherapeutic products such as biopharmaceuticals and plasma derivatives, biosafety testing services, and biopharmaceutical CDMO operations. It is one of the Asahi Kasei Group“s businesses to drive future growth. Sold since 1989, Planova™ had its product lineup…

Mehr...
Medicine Wellness Health 

ELVeS laser therapy: fewer recurrences after reflux treatment of the great saphenous vein above and below the knee

If reflux of the great saphenous vein is treated not only above but also below the knee with laser therapies such as ELVeS from biolitec, recurrences are less common Jena, 10th October 2024 – The medical technology company biolitec offers, with its ELVeS laser therapy, an endovenous laser ablation (EVLA) for minimally invasive treatment of varicose veins. A recent guideline for the treatment of varicose veins in the lower extremities recommends EVLA instead of high ligation and stripping (HLS) for the treatment of reflux in the great saphenous vein. (1)…

Mehr...
Medicine Wellness Health 

SerenAI with AI-Powered Holistic Health Pilot Program

SerenAI Invites Early Adopters to Revolutionize Holistic Health with AI-Powered Pilot Program FOR IMMEDIATE RELEASE SerenAI Invites Early Adopters to Revolutionize Holistic Health with AI-Powered Pilot Program Miami/Munich – July 24, 2024 – SerenAI, an innovative AI-Holistic-Health startup, is thrilled to announce the launch of its exclusive pilot program for its groundbreaking Holistic-Health Large Language Model (2H-LLM) platform and mobile app. Designed to empower individuals with personalized, proactive healthcare, SerenAI is seeking qualified early adopters to experience the future of well-being. Addressing the Modern Wellness Crisis with AI The world…

Mehr...

International Incontinence Day 2024: New laser therapies can prevent incontinence after urological or proctological treatment

Minimally invasive laser therapies by biolitec significantly minimize the risk of incontinence in the treatment of prostate and bladder tumors, prostate enlargement, anal fistulas, hemorrhoids and vaginal atrophy. Jena, July 3rd, 2024 – International Incontinence Day took place on June 30th. With around 6 million people affected in Germany alone, incontinence is a widespread condition that is usually kept secret because people are ashamed of it. With the LIFE, FLA, TULA, FiLaC, LHP and LaEvita laser therapies, the medical technology company biolitec offers gentle treatment options in the fields of…

Mehr...
Medicine Wellness Health 

Asahi Kasei launches membrane system to produce water for injection

Leveraging Microza™ expertise to enable lower energy consumption and higher water quality Düsseldorf, Tokyo and New York – June 13, 2024 – Asahi Kasei has announced that in April 2024 it began selling a membrane system to produce WFI (water for injection), a type of sterile water that is used for the preparation of injections. The membrane system was developed as an alternative to the conventional distillation processes for the production of WFI by leveraging system design and development capabilities of Microza™ hollow-fiber membrane for water treatment and filtration of…

Mehr...

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

Tokyo, New York, and Düsseldorf – May 28, 2024 – Asahi Kasei Corp. today announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei („the Acquisition“) through a voluntary tender offer for Calliditas („the Tender Offer“). The Tender Offer will also include a concurrent offer by Asahi Kasei to acquire all American Depositary Shares („ADS“), each representing two shares in Calliditas, which will be conducted pursuant to the…

Mehr...